| Bioactivity | RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation[1]. | ||||||||||||
| In Vivo | RBN-3143 (5 μg; 鼻内给药) 可改善类固醇耐药哮喘小鼠模型[1]。 Animal Model: | ||||||||||||
| Name | RBN-3143 | ||||||||||||
| CAS | 2360853-16-1 | ||||||||||||
| Formula | C22H28FN3O4S | ||||||||||||
| Molar Mass | 449.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Niepel M, et, al. The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models. European Respiratory Journal 2022 60: 4642. |
RBN-3143
CAS: 2360853-16-1 F: C22H28FN3O4S W: 449.54
RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.